Clinical Trials

Exelixis is conducting a broad global clinical development program for cabozantinib in a wide variety of cancer settings. The program includes multiple Exelixis-sponsored global, randomized phase 3 pivotal trials, as well as earlier stage studies conducted through our Investigator-Sponsored Trial program and our collaboration with the National Cancer Institute’s Cancer Therapy Evaluation Program.

For more information on a specific aspect of the cabozantinib clinical development program, please select an option from the menu on the left.